Pfizer Inc. (PFE)
Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial
Pfizer said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial. The data offer early evidence that the injection can be administered less frequently than existing drugs without sacrificing efficacy.
Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook
Pfizer reported fourth-quarter revenue and earnings that topped estimates even amid dwindling demand for its Covid products. The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.
Pfizer's experimental drug shows up to 12.3% weight loss in mid-stage trial
Pfizer said on Tuesday its experimental obesity drug, which it acquired through the Metsera deal, showed up to 12.3% weight loss in patients without diabetes in a mid-stage trial.
Passive Income Investors Will Love These Cheap Dividend Stocks
Passive income can help secure your retirement, but building a dependable income is not easy.
Pfizer: Buyer Beware, The Risk Outweighs The Reward
Pfizer: Buyer Beware, The Risk Outweighs The Reward
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Should You Buy, Sell or Hold Pfizer Stock Ahead of Q4 Earnings?
Pfizer PFE is set to report its fourth-quarter and full-year 2025 earnings on Feb. 3, before market open. The Zacks Consensus Estimate for sales and earnings for the fourth quarter is pegged at $16.93 billion and 57 cents per share, respectively.
Ahead of Pfizer (PFE) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of Pfizer (PFE) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Pfizer: A High-Yield Pharma At A Turning Point
Pfizer remains in the 'green zone' in 2026 despite retail investors' pessimism over the approaching LOE cycle. I believe retail investors' fears about the end of exclusivity for Pfizer's blockbusters, such as Xeljanz and Ibrance, in 2026-2028, are overblown. This is because Pfizer has a strong pipeline of FDA-approved cancer drugs and vaccines, as well as potentially best-in-class GLP-1/amylin-based therapies, MET-097i/MET-233i.
Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider
Pfizer (PFE) reached $26.5 at the closing of the latest trading day, reflecting a +2.4% change compared to its last close.
Earnings Preview: Pfizer (PFE) Q4 Earnings Expected to Decline
Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pfizer vs. Merck Stock And JNJ
In the last six months Pfizer's stock (NYSE: PFE) has underperformed Merck (NYSE: MRK) and Johnson & Johnson (NYSE: JNJ) primarily due to waning demand for its COVID-19 products, a significant upcoming patent cliff, and a lukewarm financial outlook for 2026.
